We have located links that may give you full text access.
Mucosal healing and bacterial composition in response to enteral nutrition versus steroid based induction therapy - a randomized prospective clinical trial in children with Crohn's disease.
Journal of Crohn's & Colitis 2018 December 13
Exclusive Enteral Nutrition (EEN) is as efficacious as corticosteroids (CS) to induce remission in Crohn's disease (CD), without their adverse effects. EEN seems to be more efficient than steroids to induce mucosal healing, but the underlying molecular mechanisms are only sparsely understood. We aimed in the present work to study the anti-inflammatory effects of EEN with Modulen IBD® versus CS in active pediatric CD and to assess its modulatory effects on the intestinal microbiota as compared to steroids.
MATERIAL AND METHODS: Nineteen patients with new-onset active CD (Harvey Bradshaw index HBI> 5), aged from 6 to 17 years, were included in this prospective randomized induction trial with CS (n=6) or EEN (n=13). Patients were assessed at Week 0 and 8 using clinical parameters HBI, endoscopic findings (CDEIS score) and analysis of fecal microbiota composition.
RESULTS: At 8 weeks, clinical remission (HBI<5) was achieved in 13/13 patients on EEN and 5/6 patients on steroids, while the mucosal healing rate was significantly higher in the EEN (89%) compared to steroid group (17%). There were no significant differences between groups regarding biological markers, while the intestinal microbiota profiles shifted upon EEN-induced remission to a higher proportion of Ruminococcus bacteria compared to steroid induced remission (p=0.049), with higher proportions of bacteria belonging to Clostridium in EEN-treated patients.
CONCLUSION: Both steroids and EEN induced clinical remission, however, patients with EEN-induced remission showed a higher rate of mucosal healing and this was associated with a different gut microbiota compositional shift in these children. This clinical trial was registered under the number ClinicalTrials.gov Identifier: NCT00265772.
MATERIAL AND METHODS: Nineteen patients with new-onset active CD (Harvey Bradshaw index HBI> 5), aged from 6 to 17 years, were included in this prospective randomized induction trial with CS (n=6) or EEN (n=13). Patients were assessed at Week 0 and 8 using clinical parameters HBI, endoscopic findings (CDEIS score) and analysis of fecal microbiota composition.
RESULTS: At 8 weeks, clinical remission (HBI<5) was achieved in 13/13 patients on EEN and 5/6 patients on steroids, while the mucosal healing rate was significantly higher in the EEN (89%) compared to steroid group (17%). There were no significant differences between groups regarding biological markers, while the intestinal microbiota profiles shifted upon EEN-induced remission to a higher proportion of Ruminococcus bacteria compared to steroid induced remission (p=0.049), with higher proportions of bacteria belonging to Clostridium in EEN-treated patients.
CONCLUSION: Both steroids and EEN induced clinical remission, however, patients with EEN-induced remission showed a higher rate of mucosal healing and this was associated with a different gut microbiota compositional shift in these children. This clinical trial was registered under the number ClinicalTrials.gov Identifier: NCT00265772.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app